Table 1 Basic characteristics of eligible studies
Trial | Drug | Dose(s) analysed | Median follow-up duration (years) | ClinicalTrials.gov unique identifier | Total number of trial participants | Age (years), mean | Male, n (%) | Patients with a history of DM, n (%) | Patients with a history of CKD, n (%) | Patients with a history of HF, n (%) | Patients with a history of AF, n (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
Bailey et al. [28] | Dapagliflozin | 2.5 mg, 5 mg, 10 mg (once daily) | 2.0 | NCT00528879 | 546 | 53.9 | 292 (53.5%) | 546 (100%) | NA | NA | NA |
Bailey et al. [29] | Dapagliflozin | 2.5 mg, 5 mg, 10 mg (once daily) | 2.0 | NCT00528372 | 558 | 52.2 | 276 (49.5%) | 558 (100%) | NA | NA | NA |
Bode et al. [30] | Canagliflozin | 100 mg, 300 mg (once daily) | 2.0 | NCT01106651 | 714 | 63.6 | 396 (55.5%) | 714 (100%) | NA | NA | NA |
CANTATA-MSU [31] | Canagliflozin | 100 mg, 300 mg (once daily) | 1.0 | NCT01106625 | 469 | 56.7 | 239 (51.0%) | 469 (100%) | NA | NA | NA |
CANVAS Program [32] | Canagliflozin | 100 mg, 300 mg (once daily) | 2.4 | NCT01032629; NCT01989754 | 10,142 | 63.3 | 6509 (64.2%) | 10,142 (100%) | 1774 (17.5%) | 1461 (14.4%) | 612 (6.0%) |
Cefalu et al. [33] 2015 | Dapagliflozin | 10 mg (once daily) | 1.0 | NCT01031680 | 922 | 62.9 | 624 (68.3%) | 922 (100%) | NA | NA | NA |
CREDENCE [47] | Canagliflozin | 100 mg (once daily) | 2.6 | NCT02065791 | 4401 | 63.0 | 2907 (66.1%) | 4401 (100%) | 4401 (100%) | 652 (15.8%) | NA |
DAPA-HF [49] | Dapagliflozin | 10 mg (once daily) | 1.5 | NCT03036124 | 4744 | 66.3 | 3635 (76.6%) | 1983 (41.8%) | 1926 (40.6%) | 4744 (100%) | 1818 (38.3%) |
DECLARE-TIMI 58 [34] | Dapagliflozin | 10 mg (once daily) | 4.2 | NCT01730534 | 17,160 | 63.9 | 10,738 (62.6%) | 17,160 (100%) | 8997 (52.4%) | 1724 (10.0%) | 1116 (6.5%) |
EMPA-HEART CardioLink-6 [35] | Empagliflozin | 10 mg (once daily) | 0.5 | NCT02998970 | 97 | 64.0a | 90 (92.8%) | 97 (100%) | 2 (2.1%) | 6 (6.2%) | NA |
EMPA-REG OUTCOME [36] | Empagliflozin | 10 mg, 25 mg (once daily) | 3.1 | NCT01131676 | 7020 | 63.1 | 5016 (71.5%) | 7020 (100%) | 5480 (78.1%) | 706 (10.1%) | 389 (5.5%) |
EMPA-REG RENAL [45] | Empagliflozin | 10 mg, 25 mg (once daily) | 1.0 | NCT01164501 | 738 | 63.9 | 430 (58.3%) | 738 (100%) | 738 (100%) | NA | NA |
EMPA-RESPONSE-AHF [48] | Empagliflozin | 10 mg (once daily) | 0.1 | NCT03200860 | 79 | 76a | 53 (67.1%) | 26 (32.9%) | NA | 79 (100%) | 56 (70.9%) |
Inagaki et al. [37] | Canagliflozin | 50 mg, 100 mg, 200 mg, 300 mg (once daily) | 0.3 | NCT01022112 | 383 | 57.4 | 261 (68.1%) | 383 (100%) | 29 (7.6%) | NA | NA |
Kovacs et al. [40] | Empagliflozin | 10 mg, 25 mg (once daily) | 1.3 | NCT01210001 | 498 | 54.5 | 241 (48.4%) | 498 (100%) | NA | NA | NA |
Leiter et al. [38] | Dapagliflozin | 10 mg (once daily) | 1.0 | NCT01042977 | 962 | 63.8 | 644 (66.9%) | 962 (100%) | NA | 152 (15.8%) | NA |
Mathieu et al. [41] | Dapagliflozin | 10 mg (once daily) | 0.5 | NCT01646320 | 320 | 55.1 | 146 (45.6%) | 320 (100%) | NA | NA | NA |
Rosenstock et al. [39] | Empagliflozin | 10 mg, 25 mg (once daily) | 1.5 | NCT01011868 | 494 | 58.8 | 276 (55.9%) | 494 (100%) | NA | NA | NA |
Softeland et al. [42] | Empagliflozin | 10 mg, 25 mg (once daily) | 0.5 | NCT01734785 | 332 | 55.2 | 198 (59.6%) | 332 (100%) | 166 (50.0%) | NA | NA |
VERTIS RENAL [46] | Ertugliflozin | 5 mg, 15 mg (once daily) | 1.0 | NCT01986855 | 467 | 67.3 | 231 (49.5%) | 467 (100%) | 467 (100%) | NA | NA |
Wilding et al. [43] | Dapagliflozin | 2.5 mg, 5 mg, 10 mg (once daily) | 1.0 | NCT00673231 | 800 | 59.3 | 382 (47.8%) | 800 (100%) | NA | NA | NA |
Yale et al. [44] | Canagliflozin | 100 mg, 300 mg (once daily) | 1.0 | NCT01064414 | 269 | 68.5 | 163 (60.6%) | 269 (100%) | 269 (100%) | NA | NA |